On December 11th 2020, French pharmaceutical group Sanofi and British pharma firm GSK (GlaxoSmithKline) announced that their joint development of a vaccine against Covid-19 was delayed after the first phase of clinical tests which began on September 3rd had shown “a low immune response” in the over-50 age group “likely due to an insufficient concentration of the antigen”.
You are a subscriber
Login
If you are not already a subscriber,
subscribe here
Choose a subscription offer and create your account to read all content on Mediapart
Create your account